Amendment to ASSET PURCHASE AND COLLABORATION AGREEMENTAsset Purchase and Collaboration Agreement • July 19th, 2016 • Icagen, Inc. • Services-commercial physical & biological research
This Amendment (this “Amendment”) to the Asset Purchase and Collaboration Agreement, dated as of June 26, 2015, is dated as of July 15, 2016, by and between Pfizer Research (NC), Inc. (f/k/a Icagen, Inc.), a Delaware corporation (“Pfizer” or the “Seller”), and Icagen Inc. (f/k/a XRpro Sciences, Inc.), a Delaware corporation (“Icagen” or the “Buyer”).
SECOND Amendment to ASSET PURCHASE AND COLLABORATION AGREEMENTAsset Purchase and Collaboration Agreement • August 16th, 2017 • Icagen, Inc. • Services-commercial physical & biological research
This Second Amendment (this “Amendment”), dated as of August 14, 2017 and effective as of May 31, 2017 (the “Effective Date”), to the Asset Purchase and Collaboration Agreement, dated as of June 26, 2015 and amended on July 13, 2016 (the “Original Agreement”), by and between Pfizer Research (NC), Inc. (f/k/a Icagen, Inc.), a Delaware corporation (“Pfizer” or the “Seller”), and Icagen Inc. (f/k/a XRpro Sciences, Inc.), a Delaware corporation (“Icagen” or the “Buyer”).
Asset Purchase and collaboration AgreementAsset Purchase and Collaboration Agreement • July 2nd, 2015 • XRpro Sciences, Inc. • Services-commercial physical & biological research • Delaware
This Asset Purchase and Collaboration Agreement is made and entered into as of June 26, 2015 between Icagen, Inc., a Delaware corporation (the “Seller”), and XRpro Sciences, Inc. a Delaware corporation (the “Buyer”).
